2025
Cancer Mortality
Hjartåker A, Weiderpass E, Bray F. Cancer Mortality. 2025, 171-182. DOI: 10.1016/b978-0-323-99967-0.00162-9.Peer-Reviewed Original ResearchCancer mortality burdenMortality burdenCancer mortality trendsGlobal cancer controlCancer deathCancer mortality dataHigher-income settingsProportion of deathsMortality trendsMortality dataCause of cancer deathCancer controlColorectal cancerMiddle-income economiesMeasure of progressLiver cancerCancer formsMortality rateColorectalBurdenData sourcesWorld regionsCancerDeathFrequent cause
2018
Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations
Narayan R, Creasy J, Goldman D, Gönen M, Kandoth C, Kundra R, Solit D, Askan G, Klimstra D, Basturk O, Allen P, Balachandran V, D’Angelica M, DeMatteo R, Drebin J, Kingham T, Simpson A, Abou‐Alfa G, Harding J, O’Reilly E, Butte J, Matsuyama R, Endo I, Jarnagin W. Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations. Cancer 2018, 125: 575-585. PMID: 30427539, PMCID: PMC6636637, DOI: 10.1002/cncr.31850.Peer-Reviewed Original ResearchConceptsGallbladder cancer pathogenesisErb-b2 receptor tyrosine kinase 3Gallbladder cancerJapanese patientsSMAD family member 4Overall survivalTumor mutationsAT-rich interactive domain 2Associated with worse survivalPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaAT-rich interactive domain 1AMedian mutational burdenCause of cancer deathKaplan-Meier methodKruskal-Wallis tests assessed differencesTime of surgeryTyrosine kinase 3Cancer-associated genesCatalytic subunit alphaMulti-institutional comparisonsTests assessed differencesPrimary tumorClinicopathological variablesWorse survivalMutational burden
2010
Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy.
Raldow A, Hamstra D, Kim S, Yu J. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology 2010, 24: 692-700, 702. PMID: 20718248.Peer-Reviewed Original ResearchConceptsSalvage radiation therapyAdjuvant radiation therapyRadical prostatectomyProstate cancerRadiation therapyPost-operative adjuvant radiation therapyBiochemical recurrence of prostate cancerImmediate adjuvant radiation therapySalvage external beam radiotherapyEvidence of recurrent diseaseRecurrence of prostate cancerExternal beam radiotherapyCause of cancer deathRadiotherapy volumeBeam radiotherapyBiochemical recurrenceRecurrent diseaseRandomized trialsCancer deathProstatectomySide effectsProstatePatientsCancerRadiotherapyCytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond
Seng S, Tsao C, Galsky M, Oh W. Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. Drug Discovery Today Therapeutic Strategies 2010, 7: 17-22. DOI: 10.1016/j.ddstr.2011.02.001.Peer-Reviewed Original ResearchMetastatic castration resistant prostate cancerCastration resistant prostate cancerResistant prostate cancerProstate cancerCytotoxic chemotherapyDocetaxel combination therapyCause of cancer deathChemotherapy naive patientsPhase III trialsProstate cancer therapyDocetaxel chemotherapyNaive patientsIII trialsCombination therapyProgressive diseaseNovel therapiesSurvival advantageGeneration platinumChemotherapyClinical trialsCancer deathCancer therapyCancerTherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply